Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect

Alvotech (ALVO) is set to report Q2 2025 earnings, with consensus estimates at a 26-cent loss per share on $115.4 million revenue. Key investor focus will be on the sales traction of recently launched biosimilars Simlandi and Selarsdi, which have yet to gain significant market share, and progress on pipeline candidates AVT05, AVT06, and AVT03, currently under regulatory review in the US and EU. ALVO shares have significantly underperformed year-to-date, down 26.5%, despite a strong historical earnings beat record, making future sales and pipeline advancements critical for investor sentiment.

Analysis

Alvotech (ALVO) is approaching its second-quarter 2025 earnings report with significant investor focus on its transition to a commercial-stage entity. Consensus estimates project revenues of $115.4 million and a net loss of 26 cents per share. The primary focus for the market will be the initial commercial performance of its key biosimilars, Simlandi and Selarsdi, which the report indicates have yet to achieve significant market traction since their respective launches in 2024 and Q1 2025. This commercial uncertainty is reflected in the stock's severe underperformance, having declined 26.5% year-to-date against a flat-to-positive industry trend. Offsetting these near-term commercialization challenges is a robust late-stage pipeline, including biosimilar candidates for Simponi (AVT05), Eylea (AVT06), and Prolia/Xgeva (AVT03), all of which are under regulatory review with potential decisions by the end of 2025. Strategic partnerships with Teva and an expanded collaboration with Dr. Reddy's for a Keytruda biosimilar provide external validation and commercial pathways. While Alvotech has a strong history of significant earnings beats, averaging a 244.18% surprise over the last three quarters, a neutral Earnings ESP of 0.00% suggests that past performance may not be indicative of future results as the company's financial profile shifts from licensing revenues to product sales.

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings report for specific sales figures or qualitative guidance on the market penetration of Simlandi and Selarsdi, as this is the primary determinant of current sentiment and stock performance.
• The key medium-term catalysts are regulatory decisions for pipeline assets AVT05, AVT06, and AVT03; any positive updates on these timelines or approvals could rerate the stock, irrespective of near-term revenue figures.
• Given the stock's 26.5% year-to-date decline, investors should consider that significant pessimism is already priced in, creating potential for a sharp positive reaction to better-than-expected sales uptake or accelerated pipeline news.